Tumor Location and Survival Outcomes in Lung Adenosquamous Carcinoma: A Propensity Score Matched Analysis

02 July 2020: Clinical Research

Xinlin Shi ^ABCEF* , Xiangrong Shao ^B* , Yawen Zhang ^BC , Feng Wu ^AE* , Yujian Tao ^AB*

DOI: 10.12659/MSM.922138

Med Sci Monit 2020; 26:e922138

Table 1 Baseline characteristics for patients with LASC before and after PSM.

Variables	Before PSM			After PSM
Variables	Main bronchus	Peripheral	P-value	Main bronchus	Peripheral	P-value
Age						0.395
	38	640		37	43
≥60	69	2429		69	63
Sex			0.152			0.583
Male	51	1678		51	55
Female	56	1391		55	51
Race			0.054			0.501
Black	18	309		17	17
White	84	2532		84	87
Other	5	228		5	2
Grade						0.784
I–II	10	736		10	13
III–IV	49	1529		49	46
Unknown	48	804		47	47
AJCC stage						0.346
I	4	1046		4	4
II	7	311		7	13
III	39	756		38	43
IV	57	956		57	46
T stage						0.327
T1	6	734		6	6
T2	37	1287		37	50
T3	8	250		8	6
T4	56	798		55	44
N stage						0.870
N0	16	1475		16	14
N1	13	374		13	14
N2	63	922		62	59
N3	15	298		15	19
M stage						0.131
M0	50	2113		49	60
M1	57	956		57	46
Surgery						0.549
No/unknown	94	1448		93	90
Yes	13	1621		13	16
Radiation						0.763
No/Unknown	32	1883		32	30
Yes	75	1186		74	76
Chemotherapy			0.006			0.395
No/unknown	44	1677		43	37
Yes	63	1392		63	69
PSM – Propensity Score Matching; LASC – lung adenosquamous carcinoma; AJCC – American Joint Committee on Cancer.